ANN ARBOR – Enzo Life Sciences has introduced a cancer library, a collection of 275 ready-to-use compounds for use in cancer inhibitor screening and assay development.
The SCREEN-WELL Cancer Library is comprised of compounds that are dissolved at 10 mM in DMSO and aliquoted at 100 µL per well in deep 96-well plates. It contains small molecules affecting mTOR, aurora kinases, tyrosine kinases, PI3K, HDAC, and other differing compound classes. The structural and mechanistic differences between compounds as well as the inclusion of nontoxic controls make the library a vital tool in cancer drug discovery and screening.
The library builds upon Enzo’s collection of cancer research solutions which includes DNA labeling kits for genomic analysis, enzyme activity kits, detection kits for cellular analysis, and immunoassays and antibodies for biomarker detection.
The comprehensive SCREEN-WELL Cancer Library is the newest addition to Enzo’s portfolio of SCREEN-WELL Compound Libraries, which are unique collections of small molecules provided in a ready-to-use format, amenable to high-throughput screening. The SCREEN-WELL Compound Libraries include complete documentation that highlights the physical information and mechanism of action for each compound. In addition, Enzo has the ability to re-supply individual bulk compounds or to build custom libraries.
